Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Zamboni

Showing results (111-120 of 180) with videos related to

Pageof 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenograftsWilliam C Zamboni, Sandra Strychor, Erin Joseph, et al.
The AAPS Journal|February 8, 2013
Nonaqueous gel for the transdermal delivery of a DTPA penta-ethyl ester prodrugYong Zhang, Matthew P Sadgrove, Katsuhiko Sueda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2009
Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignanciesWilliam C Zamboni, Suresh Ramalingam, David M Friedland, et al.
Journal of the National Cancer Institute|April 16, 1998
Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenograftsW C Zamboni, C F Stewart, J Thompson, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Combinatorial Treatment of Glioblastoma with Temozolomide (TMZ) Plus 5-Ethynyl-2'-deoxyuridine (EdU)Humeyra Kaanoglu, Yasemin K Akyel, Adebimpe Adefolaju, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2000
Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecanM K Ma, W C Zamboni, K M Radomski, et al.
Gynecologic Oncology|August 12, 2008
A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinomaKristopher J Kimball, T Michael Numnum, Tyler O Kirby, et al.
Cancer Chemotherapy and Pharmacology|January 4, 2001
Phase I study of docetaxel and topotecan in patients with solid tumorsK H Tkaczuk, W C Zamboni, N S Tait, et al.
Cancer Chemotherapy and Pharmacology|April 1, 2018
Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancerJames D Byrne, Mohammad R N Jajja, Adrian T O'Neill, et al.
Molecular Pharmaceutics|May 13, 2016
Design, Synthesis, and Characterization of Folate-Targeted Platinum-Loaded Theranostic Nanoemulsions for Therapy and Imaging of Ovarian CancerNiravkumar R Patel, Aleksandr Piroyan, Abbegial H Nack, et al.
Pageof 18

Showing results (111-120 of 180) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenograftsWilliam C Zamboni, Sandra Strychor, Erin Joseph, et al.
The AAPS Journal|February 8, 2013
Nonaqueous gel for the transdermal delivery of a DTPA penta-ethyl ester prodrugYong Zhang, Matthew P Sadgrove, Katsuhiko Sueda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2009
Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignanciesWilliam C Zamboni, Suresh Ramalingam, David M Friedland, et al.
Journal of the National Cancer Institute|April 16, 1998
Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenograftsW C Zamboni, C F Stewart, J Thompson, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Combinatorial Treatment of Glioblastoma with Temozolomide (TMZ) Plus 5-Ethynyl-2'-deoxyuridine (EdU)Humeyra Kaanoglu, Yasemin K Akyel, Adebimpe Adefolaju, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2000
Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecanM K Ma, W C Zamboni, K M Radomski, et al.
Gynecologic Oncology|August 12, 2008
A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinomaKristopher J Kimball, T Michael Numnum, Tyler O Kirby, et al.
Cancer Chemotherapy and Pharmacology|January 4, 2001
Phase I study of docetaxel and topotecan in patients with solid tumorsK H Tkaczuk, W C Zamboni, N S Tait, et al.
Cancer Chemotherapy and Pharmacology|April 1, 2018
Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancerJames D Byrne, Mohammad R N Jajja, Adrian T O'Neill, et al.
Molecular Pharmaceutics|May 13, 2016
Design, Synthesis, and Characterization of Folate-Targeted Platinum-Loaded Theranostic Nanoemulsions for Therapy and Imaging of Ovarian CancerNiravkumar R Patel, Aleksandr Piroyan, Abbegial H Nack, et al.
Pageof 18